大剂量阿糖胞苷对急性髓细胞白血病缓解后治疗的无病生存影响  

HIGH-DOSE CYTARABINE AS INTENSIVE POSTREMISSION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA: EFFECT ON LONG-TERM DISEASE-FREE SURVIVAL

作　　者：杨科[1] 何学鹏[1] 唐晓东[1] 梅巍 滕爱萍 张凡[1] 

机构地区：[1]中国人民解放军北京军区总医院血液科

出　　处：《中华内科杂志》1994年第7期470-473,共4页Chinese Journal of Internal Medicine

摘　　要：单用大剂量阿糖胞普（ＨＤ－Ａ）对３７例急性髓细胞白血病（ＡＭＬ）患者在缓解后进行强化治疗，并以同期未用ＨＤ－Ａ强化治疗的患者为对照，试图探讨ＨＤ－Ａ对无病生存的影响。结果表明治疗组的中位缓解期为１６．０个月，复发率为４８．６％对照组的中位缓解期为１０．０个月，复发率为７５．０％Ｋａｐｌａｎ－Ｍｅｉｅｒ曲线示治疗组的３年和５年预期无病生存分别为５０．２％和４３．０％对照组分别为３１．０％１６．７％两组差异有显著性（Ｐ＜０．０５）。提示ＨＤ－Ａ能延长ＡＭＬ患者的无病生存和减少复发。n an attempt to increase the proportion of patients with acute myelogenous leukemia(AML) re-maining in long-term disease-free survival(DFS).37 patients with AML in complete remission(CR)received HD-Ara-C(1.0g / m￣2) as intensive postremission therapy. The results were compared with those of 28 patients who did not reeeive HD-Ara-C therapy(control group) during the same peroid.With a median follow-up of 21.7 months(6.9-77.3),median CR duration was 16.0 months for HD-Ara-Cgroup and 10.0 months(2.0-75.2)for the control group. Relapse rates were 48.6%(18 / 37)and 75%(21 / 28),respectively.The actuarial 3 and 5 years DFS was 50.2% and 43% for HD-Ara-C group versus 31 % and 16.7% for the control group.There was significant difference(P<0.05).This re-sult suggested that HD-Ara-C could prolong DFS and reduce relapse in patients with AML.

关 键 词：白血病 髓细胞性 阿糖胞苷 

分 类 号：R733.710.7[医药卫生—肿瘤]